强化降压治疗的靶器官保护效应及其临床预后价值

丁彦春

大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 193 -198.

PDF (504KB)
大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 193 -198. DOI: 10.11724/jdmu.2026.03.01
专家述评

强化降压治疗的靶器官保护效应及其临床预后价值

作者信息 +

Target organ protection and clinical prognostic value of intensive blood pressure lowering therapy

Author information +
文章历史 +
PDF (515K)

摘要

高血压是全球范围内最常见的心血管疾病之一,长期血压控制不佳可导致心、脑、肾、眼等靶器官结构与功能损伤。早期安全实现血压的有效控制,已成为全球医疗体系亟待解决的重大任务。然而,目前关于早期强化降压的获益及安全性平衡、人群适用性及临床应用仍存在争议。本文系统综述强化降压治疗的发展历程、国际指南目标差异,以及特殊人群的血压控制目标与循证证据。同时阐述强化降压对心脏、脑血管及肾脏靶器官的保护机制与临床获益。现有证据表明,在患者耐受的前提下,强化降压可带来更多获益。但降压方式需遵循个体化原则,小剂量起步、缓慢达标。未来应进一步探索精准化降压方案,加强长期安全性与成本效益研究,推动高血压治疗从“适度控制”向“精准强化”转变。

Abstract

Hypertension is one of the most prevalent cardiovascular diseases globally. Prolonged inadequate blood pressure control can lead to structural and functional damage in target organs, including the heart, brain, kidneys and eyes. Achieving effective and safe blood pressure control at an early stage has become a critical priority for healthcare systems worldwide. However, controversies persist regarding the balance between the benefits and safety of early intensive blood pressure lowering, its applicability across diverse populations, and its clinical implementation. This review systematically summarizes the development of intensive blood pressure lowering therapy, variations in target blood pressure values among international guidelines, and evidence-based recommendations for blood pressure control targets for special populations. It also elucidates the underlying protective mechanisms and clinical benefits of intensive blood pressure lowering on target organs. Current evidence indicates that intensive blood pressure lowering can confer additional benefits in patients who tolerate it well. However, treatment strategies should adhere to individualized principles, including low-dose initiation and gradual target achievement. Future research should focus on precision blood pressure lowering strategies, as well as long-term safety and cost-effectiveness, to facilitate the transition of hypertension management from "moderate control" to "precision intensification".

关键词

高血压 / 强化降压 / 靶器官保护 / 临床获益

Key words

hypertension / intensive blood pressure lowering / target organ protection / clinical benefit

引用本文

引用格式 ▾
丁彦春. 强化降压治疗的靶器官保护效应及其临床预后价值[J]. 大连医科大学学报, 2026, 48(3): 193-198 DOI:10.11724/jdmu.2026.03.01

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Mills KT, Krousel-Wood M, Peacock EM, et al. Multifaceted strategies for hypertension control in low-income patients[J]. N Engl J Med, 2026, 394(14): 1376-1387. DOI: 10.1056/NEJMoa2504068.

[2]

Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023[J]. J Am Coll Cardiol, 2025, 86(22): 2167-2243. DOI: 10.1016/j.jacc.2025.08.015.

[3]

国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告 2024 概要[J]. 中国循环杂志, 2025, 40(6): 521-559. DOI: 10.3969/j.issn.1000-3614.2025.06.001.

[4]

O'Connell SS, Whelton PK, Mills KT. Global trends in hypertension prevalence, awareness, treatment, and control[J]. Curr Opin Nephrol Hypertens, 2026, 35(2): 174-180. DOI: 10.1097/mnh.0000000000001151.

[5]

McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension[J]. Eur Heart J, 2024, 45(38): 3912-4018. DOI: 10.1093/eurheartj/ehae178.

[6]

Writing Committee Members, Jones DW, Ferdinand KC, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. Circulation, 2025, 152(11): e114-e218. DOI: 10.1161/CIR.0000000000001356.

[7]

中国高血压防治指南修订委员会, 高血压联盟, 中国医疗保健国际交流促进会高血压分会, 等. 中国高血压防治指南 (2024 年修订版)[J]. 中华高血压杂志 (中英文), 2024, 32(7): 603-700.

[8]

Kario K. Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated ‘anticipation medicine’ for zero cardiovascular event[J]. Prog Cardiovasc Dis, 2016, 59(3): 262-281. DOI: 10.1016/j.pcad.2016.04.001.

[9]

Herberth J, Soliman KM, Fülöp T, et al. How we got where we are in blood pressure targets[J]. Curr Hypertens Rep, 2021, 23(6): 33. DOI: 10.1007/s11906-021-01143-8.

[10]

Chalmers J. Hypertension optimal treatment (HOT) study: a brilliant concept, but a qualified success[J]. J Hypertens, 1998, 16(10): 1403-1405. DOI: 10.1097/00004872-199816100-00002.

[11]

Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report[J]. ACC Curr J Rev, 2003, 12(4): 31-32. DOI: 10.1016/S1062-1458(03)00270-8.

[12]

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J]. Hypertension, 2018, 71(6): 1269-1324. DOI: 10.1161/HYP.0000000000000066.

[13]

Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens, 2023, 41(12): 1874-2071. DOI: 10.1097/HJH.0000000000003480.

[14]

Brown C, Clark D, Jones DW. Updates in the 2025 AHA/ACC hypertension guideline[J]. Curr Hypertens Rep, 2026, 28(1): 19. DOI: 10.1007/s11906-026-01372-9.

[15]

Al-Makki A, DiPette D, Whelton PK, et al. Hypertension pharmacological treatment in adults: a World Health Organization guideline executive summary[J]. Hypertension, 2022, 79(1): 293-301. DOI: 10.1161/HYPERTENSIONAHA.121.18192.

[16]

中华医学会糖尿病学分会糖尿病与肥胖学组, 中国高血压联盟, 祝之明, 等. 成人 2 型糖尿病的高血压管理中国专家共识[J]. 中国循证医学杂志, 2025, 25(6): 621-632.

[17]

中国老年医学学会高血压分会, 北京高血压防治协会, 国家老年疾病临床医学研究中心 (中国人民解放军总医院, 首都医科大学宣武医院). 中国老年高血压管理指南 2023[J]. 中华高血压杂志, 2023, 31(6): 508-538. DOI: 10.16439/j.issn.1673-7245.2023.06.003.

[18]

王增武, 王圣, 冯彩霞, 等. 中国卒中患者高血压管理专家共识[J]. 中国卒中杂志, 2024, 19(6): 672-698. DOI: 10.3969/j.issn.1673-5765.2024.06.009.

[19]

Kućmierz J, Frąk W, Młynarska E, et al. Molecular interactions of arterial hypertension in its target organs[J]. Int J Mol Sci, 2021, 22(18): 9669. DOI: 10.3390/ijms22189669.

[20]

Huang XD, Huang XW, Pan MD, et al. Effect of early endothelial function improvement on subclinical target organ damage in hypertensives[J]. Sci Rep, 2024, 14(1): 16078. DOI: 10.1038/s41598-024-67143-1.

[21]

Haze T, Katsurada K, Sakata S, et al. Effect of intensive versus standard blood pressure control on cardiovascular outcomes in adult patients with hypertension: a systematic review and meta-analysis[J]. Hypertens Res, 2025, 48(6): 1846-1858. DOI: 10.1038/s41440-025-02131-0.

[22]

Ascher SB, de Lemos JA, Lee M, et al. Intensive blood pressure lowering in patients with malignant left ventricular hypertrophy[J]. J Am Coll Cardiol, 2022, 80(16): 1516-1525. DOI: 10.1016/j.jacc.2022.08.735.

[23]

Wang LL, Yi JY, Wang W, et al. Impact of first-line antihypertensive drug class and intensity on NT-proBNP improvement and cardiovascular outcomes among hypertensive patients with pre-heart failure: findings from SPRINT trial[J]. Hypertens Res, 2024, 47(12): 3447-3457. DOI: 10.1038/s41440-024-01873-7.

[24]

Liu JM, Li Y, Ge JZ, et al. Lowering systolic blood pressure to less than 120 mmHg versus less than 140 mmHg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial[J]. Lancet, 2024, 404(10449): 245-255. DOI: 10.1016/S0140-6736(24)01028-6.

[25]

Wang B, Sun Y, Li Y, et al. Intensive BP control and cognitive function: a randomized clinical trial[J]. Hypertension, 2026, 83(4): e26572. DOI: 10.1161/hypertensionaha.125.26572.

[26]

Bajwa E, Klegeris A. Neuroinflammation as a mechanism linking hypertension with the increased risk of Alzheimer’s disease[J]. Neural Regen Res, 2022, 17(11): 2342-2346. DOI: 10.4103/1673-5374.336869.

[27]

Lopez R, Copeland T, McCulloch C, et al. Additive effects of intensive BP control and ACE inhibition on suppression of proteinuria in patients with CKD[J]. J Hum Hypertens, 2023, 37(5): 419-421. DOI: 10.1038/s41371-023-00823-z.

[28]

Wright JT Jr, Whelton PK, Johnson KC, et al. SPRINT revisited: updated results and implications[J]. Hypertension, 2021, 78(6): 1701-1710. DOI: 10.1161/hypertensionaha.121.17682.

[29]

Rahimi K, Bidel Z, Nazarzadeh M, et al. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis[J]. Lancet, 2021, 398(10305): 1053-1064. DOI: 10.1016/S0140-6736(21)01921-8.

[30]

Zhang WL, Zhang SY, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension[J]. N Engl J Med, 2021, 385(14): 1268-1279. DOI: 10.1056/NEJMoa2111437.

[31]

Bi YF, Li M, Liu Y, et al. Intensive blood-pressure control in patients with type 2 diabetes[J]. N Engl J Med, 2025, 392(12): 1155-1167. DOI: 10.1056/nejmoa2412006.

[32]

Guo XF, Sun GZ, Xu Y, et al. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials[J]. Lancet, 2025, 406(10507): 1009-1019. DOI: 10.1016/S0140-6736(25)01391-1.

[33]

Li JG, Somers VK, Gao X, et al. Evaluation of optimal diastolic blood pressure range among adults with treated systolic blood pressure less than 130 mm Hg[J]. JAMA Netw Open, 2021, 4(2): e2037554. DOI: 10.1001/jamanetworkopen.2020.37554.

[34]

公绪合, 丁彦春, 张鹏强. 降压治疗中的 J 形曲线[J]. 中华高血压杂志, 2011, 19(8): 744-749. DOI: 10.16439/j.cnki.1673-7245.2011.08.010.

[35]

Park S, Shin ES, Ihm SH, et al. Optimizing systolic blood pressure targets for elderly hypertensive patients: a meta-analysis of mortality, cardiovascular outcomes, and adverse events[J]. Clin Hypertens, 2025, 31: e25. DOI: 10.5646/ch.2025.31.e25.

基金资助

大连市登峰计划科研项目(2021024)

AI Summary AI Mindmap
PDF (504KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉